CG
CBAY

Cutler Group’s Cymabay Therapeutics CBAY Stock Holding History

Cutler Group’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-200
Closed -$3.56K – 4545
2023
Q3 		$2K Buy
+200
New +$2.65K ﹤0.01% 3390
2020
Q4 		– Sell
-600
Closed -$4K – 5666
2020
Q3 		$4K Hold
600
– – ﹤0.01% 3742
2020
Q2 		$2K Sell
600
-500
-45% -$1.44K ﹤0.01% 3881
2020
Q1 		$1K Hold
1,100
– – ﹤0.01% 3860
2019
Q4 		$2K Hold
1,100
– – ﹤0.01% 3551
2019
Q3 		$5K Sell
1,100
-4,100
-79% -$24.8K ﹤0.01% 3092
2019
Q2 		$37K Buy
+5,200
New +$58.9K ﹤0.01% 1781
2019
Q1 		– Sell
-2,400
Closed -$25.5K – 4923
2018
Q4 		$18K Buy
+2,400
New +$22.8K ﹤0.01% 2191
2018
Q2 		– Sell
-800
Closed -$10K – 5072
2018
Q1 		$10K Buy
800
+400
+100% +$4.97K ﹤0.01% 2814
2017
Q4 		$3K Buy
+400
New +$3.42K ﹤0.01% 4022

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Cutler Group's CBAY Position: Q4 2023 in Review

Cutler Group sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 200 shares — an estimated $3.56K sold.

Cutler Group first reported a position in CBAY in Q4 2017 and held it in 10 quarters. The position peaked at $37K in Q2 2019. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

  • Cutler Group reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 200 Cymabay Therapeutics shares in Q4 2023, an estimated $3.56K.
  • Cutler Group first reported a position in Cymabay Therapeutics in Q4 2017 and held it in 10 quarters.
  • Cutler Group's Cymabay Therapeutics position peaked at $37K in Q2 2019.
  • 200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.